Replies to post #96362 on Biotech Values

[ghmm]

I expected given their management of known AE's the SVR rate would be even better especially since it seems they cut the drop out number substantially. But I didn't sit down and do the math to see if the number is above what would have been expected.

EDIT: OK your right (of course) I went back over the phase 2 results and the improvement over placebo taking into account the reduced drop outs looks improved especially considering this is a much larger study.

[DewDiligence]

VRTX is plugging the rate of anemia discontinuations: 0.8%, 3.3%, and 0.6% for the ‘12+12’, ‘8+24’, and control arms, respectively. We know why they are doing this.

[DewDiligence]

would be nice to see what % were good at week 24.

70% of the patients who achieved SVR in the Telaprevir arms got 24 weeks of total treatment, while 30% of the patients who achieved SVR in the Telaprevir arms got 48 weeks of total treatment. There was no difference between the two Telaprevir arms in this regard.